Literature DB >> 26064314

MEK1 expression and its relationship with clinical pathological features in hepatocellular carcinoma.

Renhua Gong1, Dengqun Sun1, Xingguo Zhong1, Yanjun Sun1, Li Li2.   

Abstract

BACKGROUND: MEK1 is overexpressed in various human carcinomas, but the role of MEK1 is not well unknown in hepatocellular carcinoma (HCC). In the present study, we aimed to explore MEK1 expression of in HCC tissues, and to evaluate its relationship with clinical pathological features.
METHODS: Expressions of MEK1 were detected by western blot assay, real-time quantitative PCR and immunohistochemical (IHC) staining in 30 HCC tissues and their adjacent normal tissues. Pearson Chi-square test was used to analyze the relationship between MEK1 expression and clinical pathological features. The survival curve was drawn by Kaplan-Meier method, and survival was analyzed by Lon-rank test.
RESULTS: The expression of MEK1 mRNA in HCC tissues was significantly higher than that in adjacent normal tissues and so was the expression of MEK1 protein. In the 30 specimens, 70% was with Tumor/Normal ratio > 2, 10% with Tumor/Normal ratio < 1 and 20% with 1 < Tumor/Normal ratio < 2. The mean survival time in high MEK1 expression group was significantly lower than that in low MEK1 expression group (Log-rank value = 11.946, P < 0.01).
CONCLUSION: MEK1 expressions in HCC tissues were significantly higher than that in adjacent normal tissues, which indicated that MEK1 was involved in the genesis and development of HCC. Moreover, it was closely related to the postoperative survival time of patients with HCC.

Entities:  

Keywords:  HCC; MEK1; mRNA; survival analysis

Year:  2015        PMID: 26064314      PMCID: PMC4443148     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

1.  Chronic hepatitis B.

Authors:  A S Lok; B J McMahon
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

2.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

3.  Authors' response: virus-host interactions in HBV-related hepatocellular carcinoma: more to be revealed?

Authors:  Qian Cao; Sandrine Imbeaud; Shalini Datta; Jessica Zucman-Rossi
Journal:  Gut       Date:  2014-10-20       Impact factor: 23.059

4.  MEK inhibitor for gastric cancer with MEK1 gene mutations.

Authors:  Shunsuke Sogabe; Yosuke Togashi; Hiroaki Kato; Akihiro Kogita; Takuro Mizukami; Yoichi Sakamoto; Eri Banno; Masato Terashima; Hidetoshi Hayashi; Marco A de Velasco; Kazuko Sakai; Yoshihiko Fujita; Shuta Tomida; Takushi Yasuda; Yoshifumi Takeyama; Kiyotaka Okuno; Kazuto Nishio
Journal:  Mol Cancer Ther       Date:  2014-09-24       Impact factor: 6.261

5.  Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases.

Authors:  Yu-Yun Shao; Ming-Chih Ho; Ann-Lii Cheng; Chih-Hung Hsu
Journal:  J Formos Med Assoc       Date:  2012-08-25       Impact factor: 3.282

6.  Effect of the HBV whole-X gene on the expression of hepatocellular carcinoma associated proteins.

Authors:  Yu Zhang; Hongli Liu; Meiling Cui; Jinfeng Liu; Ruitian Yi; Yinghua Niu; Tianyan Chen; Yingren Zhao
Journal:  J Microbiol Immunol Infect       Date:  2014-10-12       Impact factor: 4.399

7.  Current clinical uses of the biomarkers for hepatocellular carcinoma.

Authors:  Jiwei Huang; Yong Zeng
Journal:  Drug Discov Ther       Date:  2014-04

Review 8.  Molecular viral oncology of hepatocellular carcinoma.

Authors:  Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

9.  A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.

Authors:  M Biselli; F Conti; A Gramenzi; M Frigerio; A Cucchetti; G Fatti; M D'Angelo; M Dall'Agata; E G Giannini; F Farinati; F Ciccarese; P Andreone; M Bernardi; F Trevisani
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

10.  Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: retrospective study of the Milan and Hangzhou criteria.

Authors:  Zhenhua Hu; Jie Zhou; Zhiwei Li; Jie Xiang; Ze Qian; Jian Wu; Min Zhang; Shusen Zheng
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  1 in total

1.  miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker.

Authors:  Feng Li; Feiran Wang; Changlai Zhu; Qun Wei; Tianyi Zhang; You Lang Zhou
Journal:  Int J Nanomedicine       Date:  2018-04-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.